Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Reblozyl luspatercept beta-thalassemia associated anemia Reimburse with clinical criteria and/or conditions Complete
Reblozyl luspatercept Myelodysplastic syndromes-associated anemia Reimburse with clinical criteria and/or conditions Complete
Relistor Methylnaltrexone bromide Constipation, Opioid-induced Do not list Complete
Relpax Eletriptan hydrobromide Migraine Do not list Complete
Remicade Infliximab Ulcerative Colitis Do not list Complete
Remodulin Treprostinil sodium Pulmonary arterial hypertension (NYHA Class III and IV patients) Do not list Complete
Remodulin Treprostinil sodium Pulmonary arterial hypertension (NYHA Class III and IV patients) List with clinical criteria and/or conditions Complete
Remsima infliximab Crohn’s disease Active
Remsima infliximab Ulcerative Colitis Active
Remsima infliximab Rheumatoid arthritis Reimburse with clinical criteria and/or conditions Complete